Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Oct 22;62(17):1575-9.
doi: 10.1016/j.jacc.2013.06.051. Epub 2013 Aug 21.

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes)

John J Albers  1 , April Slee, Kevin D O'Brien, Jennifer G Robinson, Moti L Kashyap, Peter O Kwiterovich Jr, Ping Xu, Santica M Marcovina
Affiliations
Randomized Controlled Trial

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes)

John J Albers et al. J Am Coll Cardiol. .

Abstract

Objectives: This study sought to examine the relationship between baseline and on-study apolipoproteins (apo) A-1 and B and lipoprotein(a) [Lp(a)] levels and the development of subsequent cardiovascular (CV) events in the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) trial.

Background: Niacin has been reported to lower apoB and Lp(a) and to raise apoA-1.

Methods: Individuals with CV disease and low baseline levels of high-density lipoprotein cholesterol were randomized to simvastatin plus placebo or simvastatin, plus extended-release niacin ([ERN], 1,500 to 2,000 mg/day), with ezetimibe added as needed, in both groups, to maintain an on-treatment low-density lipoprotein cholesterol in the range of 40 to 80 mg/dl. Hazard ratios (HRs) were used to evaluate the relationship between levels of apoA-1, apoB, and Lp(a), and CV events in each treatment group.

Results: Baseline apoB and the apoB/apoA-I ratio were significantly predictive of CV events only for the placebo group (HR: 1.17 [p = 0.018] and HR: 1.19 [p = 0.016]). Baseline and on-study Lp(a) were predictive of CV events in both simvastatin plus placebo (baseline HR: 1.24 [p = 0.002] and on-study HR: 1.21 [p = 0.017]) and the simvastatin plus ERN group (baseline HR: 1.25 [p = 0.001] and on-study HR: 1.18 [p = 0.028]). The ERN modestly increased 1-year apoA-1 (7%), decreased apoB (13%), decreased the ApoB/ApoA-1 ratio (19%), and decreased Lp(a) 21%, but did not reduce CV events.

Conclusions: Lp(a) was associated with increased CV risk in both treatment groups indicating that it contributes to residual CV risk. However, there was no evidence that ERN reduced CV risk, despite favorable lipoprotein changes.

Keywords: Apo; CV; ELISA; ERN; HDL-C; HR; LDL; LDL-C; Lp(a); apolipoprotein; apolipoproteins; cardiovascular; cardiovascular risk; enzyme-linked immunoadsorbent assay; extended-release niacin; hazard ratio; high-density lipoprotein cholesterol; lipoprotein(a); low-density lipoprotein; low-density lipoprotein cholesterol; niacin; simvastatin.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Comparison of AIM-HIGH and Framingham baseline Lp(a) distribution
Histogram of baseline Lp(a) [nmol/L] for each study. Lp(a) distributions are compared using the Wilcoxon test.
Figure 2
Figure 2. Time to first cardiovascular event for statin + placebo arm by baseline Lp(a) quartile
Kaplan-Meier curves show time to first CV event for quartiles of baseline Lp(a) [nmol/L] in patients randomized to LDL-lowering therapy + placebo. HR and 95% CI are based on Cox Proportional Hazards regression, including terms for gender and diabetes. HR = Hazard Ratio; CI = Confidence Interval
Figure 3
Figure 3. Time to first cardiovascular event for statin + niacin arm by baseline Lp(a) quartiles
Kaplan-Meier curves show time to first CV event for quartiles of baseline Lp(a) [nmol/L] in patients randomized to LDL-lowering therapy + niacin. HR and 95% CI are based on Cox Proportional Hazards regression, including terms for gender and diabetes. HR = Hazard Ratio; CI = Confidence Interval
See this image and copyright information in PMC

References

    1. Boden WE, Probstfield JL, Anderson T, et al. The AIM-HIGH Investigators. Niacin in patients with Low HDL Cholesterol levels receiving intensive Statin therapy. N Engl J Med. 2011;365:2255–67. - PubMed
    1. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effects of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurement of lipoprotein(a) Clin Chem. 1995;41:246–55. - PubMed
    1. Lamon-Fava S, Marconvina SM, Albers JJ, et al. Lp(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res. 2011;52:1181–7. - PMC - PubMed
    1. Maher VMG, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a) JAMA. 1995;274:1771–74. - PubMed
    1. Erquo S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–23. - PMC - PubMed

Publication types

MeSH terms